View Item 

Show simple item record

Comparison of Changes in the Lipid Profile of Postmenopausal Women With Early Stage Breast Cancer Treated With Exemestane or Letrozole
dc.contributor.authorBell, Lauren Nicoleen_US
dc.contributor.authorNguyen, Anne Thi Phuongen_US
dc.contributor.authorLi, Langen_US
dc.contributor.authorDesta, Zeruesenayen_US
dc.contributor.authorHenry, N. Lynnen_US
dc.contributor.authorHayes, Daniel F.en_US
dc.contributor.authorWolff, Antonio C.en_US
dc.contributor.authorStearns, Vereden_US
dc.contributor.authorStorniolo, Anna Mariaen_US
dc.contributor.authorFlockhart, David A.en_US
dc.date.accessioned2013-04-08T20:49:31Z
dc.date.available2014-02-03T16:21:44Zen_US
dc.date.issued2012-12en_US
dc.identifier.citationBell, Lauren Nicole; Nguyen, Anne Thi Phuong; Li, Lang; Desta, Zeruesenay; Henry, N. Lynn; Hayes, Daniel F.; Wolff, Antonio C.; Stearns, Vered; Storniolo, Anna Maria; Flockhart, David A. (2012). "Comparison of Changes in the Lipid Profile of Postmenopausal Women With Early Stage Breast Cancer Treated With Exemestane or Letrozole." The Journal of Clinical Pharmacology 52(12). <http://hdl.handle.net/2027.42/97162>en_US
dc.identifier.issn0091-2700en_US
dc.identifier.issn1552-4604en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/97162
dc.publisherBlackwell Publishing Ltden_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherLetrozoleen_US
dc.subject.otherBreast Canceren_US
dc.subject.otherLipid Profileen_US
dc.subject.otherExemestaneen_US
dc.subject.otherCholesterolen_US
dc.titleComparison of Changes in the Lipid Profile of Postmenopausal Women With Early Stage Breast Cancer Treated With Exemestane or Letrozoleen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbsecondlevelPediatricsen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Internal Medicine and Breast Oncology Program, Comprehensive Cancer Center, University of Michigan Health and Hospitals System, Ann Arbor, Michiganen_US
dc.contributor.affiliationotherDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Marylanden_US
dc.contributor.affiliationotherThe Consortium on Breast Cancer Pharmacogenomics (COBRA)en_US
dc.contributor.affiliationotherDepartment of Medicine, Indiana University, Indianapolis, Indianaen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/97162/1/0091270011424153.pdf
dc.identifier.doi10.1177/0091270011424153en_US
dc.identifier.sourceThe Journal of Clinical Pharmacologyen_US
dc.identifier.citedreferenceLove RR, Wiebe DA, Feyzi JM, Newcomb PA, Chappell RJ. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst. 1994; 86 ( 20 ): 1534 – 1539.en_US
dc.identifier.citedreferenceGeisler J, King N, Anker G, et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res. 1998; 4 ( 9 ): 2089 – 2093.en_US
dc.identifier.citedreferenceGeisler J, Haynes B, Anker G, Dowsett M, Lonning PE. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, crossover study. J Clin Oncol. 2002; 20 ( 3 ): 751 – 757.en_US
dc.identifier.citedreferenceDowsett M, Cuzick J, Ingle J, et al. Meta‐analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010; 28 ( 3 ): 509 – 518.en_US
dc.identifier.citedreferenceWiner EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor‐positive breast cancer: status report 2004. J Clin Oncol. 2005; 23 ( 3 ): 619 – 629.en_US
dc.identifier.citedreferenceMiller WR. Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer. Semin Oncol. 2003; 30 ( 4 ) (Suppl 14): 3 – 11.en_US
dc.identifier.citedreferenceVisvanathan K, Chlebowski RT, Hurley P, et al. American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol. 2009; 27 ( 19 ): 3235 – 3258.en_US
dc.identifier.citedreferenceBaum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002; 359 ( 9324 ): 2131 – 2139.en_US
dc.identifier.citedreferenceGoss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early‐stage breast cancer. N Engl J Med. 2003; 349 ( 19 ): 1793 – 1802.en_US
dc.identifier.citedreferenceCoombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004; 350 ( 11 ): 1081 – 1092.en_US
dc.identifier.citedreferenceLonning PE, Geisler J, Krag LE, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol. 2005; 23 ( 22 ): 5126 – 5137.en_US
dc.identifier.citedreferenceFrancini G, Petrioli R, Montagnani A, et al. Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids. Br J Cancer. 2006; 95 ( 2 ): 153 – 158.en_US
dc.identifier.citedreferenceMontagnani A, Gonnelli S, Cadirni A, et al. The effects on lipid serum levels of a 2‐year adjuvant treatment with exemestane after tamoxifen in postmenopausal women with early breast cancer. Eur J Intern Med. 2008; 19 ( 8 ): 592 – 597.en_US
dc.identifier.citedreferenceMarkopoulos C, Polychronis A, Dafni U, et al. Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy. Ann Oncol. 2009; 20 ( 1 ): 49 – 55.en_US
dc.identifier.citedreferenceMarkopoulos C, Chrissochou M, Michailidou A, et al. Effect of exemestane on the lipidemic profile of postmenopausal operable breast cancer patients following 5–7 years of adjuvant tamoxifen: preliminary results of the ATENA substudy. Anticancer Drugs. 2005; 16 ( 8 ): 879 – 883.en_US
dc.identifier.citedreferenceMarkopoulos C, Dafni U, Misitzis J, et al. Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy. Breast Cancer Res. 2009; 11 ( 3 ): R35.en_US
dc.identifier.citedreferenceElisaf MS, Bairaktari ET, Nicolaides C, et al. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer. 2001; 37 ( 12 ): 1510 – 1513.en_US
dc.identifier.citedreferenceWasan KM, Goss PE, Pritchard PH, et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol. 2005; 16 ( 5 ): 707 – 715.en_US
dc.identifier.citedreferenceHenry NL, Giles JT, Ang D, et al. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat. 2008; 111 ( 2 ): 365 – 372.en_US
dc.identifier.citedreferenceIwase H. Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer. Breast Cancer. 2008; 15 ( 4 ): 278 – 290.en_US
dc.identifier.citedreferenceDziewulska‐Bokiniec A, Wojtacki J, Skokowski J, Kortas B. The effect of tamoxifen treatment on serum cholesterol fractions in breast cancer women. Neoplasma. 1994; 41 ( 1 ): 13 – 16.en_US
dc.identifier.citedreferenceThangaraju M, Kumar K, Gandhirajan R, Sachdanandam P. Effect of tamoxifen on plasma lipids and lipoproteins in postmenopausal women with breast cancer. Cancer. 1994; 73 ( 3 ): 659 – 663.en_US
dc.identifier.citedreferenceGrey AB, Stapleton JP, Evans MC, Reid IR. The effect of the anti‐estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab. 1995; 80 ( 11 ): 3191 – 3195.en_US
dc.identifier.citedreferenceVrbanec D, Reiner Z, Belev B, Plestina S. Changes in serum lipid and lipoprotein levels in postmenopausal patients with node‐positive breast cancer treated with tamoxifen. Tumori. 1998; 84 ( 6 ): 687 – 690.en_US
dc.identifier.citedreferenceSharma D, Sharma U, Bhatnagar VB, Singh VS. A study of the effect of tamoxifen on serum lipoprotein profiles in premenopausal and postmenopausal women with breast carcinoma and associated risk of cardiovascular disease. Indian J Med Sci. 2001; 55 ( 7 ): 359 – 365.en_US
dc.identifier.citedreferenceNtukidem NI, Nguyen AT, Stearns V, et al. Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen. Clin Pharmacol Ther. 2008; 83 ( 5 ): 702 – 710.en_US
dc.identifier.citedreferenceAriazi EA, Leitao A, Oprea TI, et al. Exemestane's 17‐hydroxylated metabolite exerts biological effects as an androgen. Mol Cancer Ther. 2007; 6 ( 11 ): 2817 – 2827.en_US
dc.identifier.citedreferenceLovejoy JC, Bray GA, Bourgeois MO, et al. Exogenous androgens influence body composition and regional body fat distribution in obese postmenopausal women: a clinical research center study. J Clin Endocrinol Metab. 1996; 81 ( 6 ): 2198 – 2203.en_US
dc.identifier.citedreferencePuntoni M, Decensi A. The rationale and potential of cancer chemoprevention with special emphasis on breast cancer. Eur J Cancer. 2009; 45 ( suppl 1 ): 346 – 354.en_US
dc.identifier.citedreferenceJanni W, Hepp P. Adjuvant aromatase inhibitor therapy: outcomes and safety. Cancer Treat Rev. 2010; 36 ( 3 ): 249 – 261.en_US
dc.identifier.citedreferenceEwer MS, Gluck S. A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health. Cancer. 2009; 115 ( 9 ): 1813 – 1826.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
0091270011424153.pdf
Size:
653.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.